DSIP dosage: reported doses and schedule
An experimental sleep peptide with small, mixed human studies and no FDA-approved dose.
Also called: Delta sleep-inducing peptide, Delta-sleep-inducing peptide, Emideltide.
Sleep peptides · Experimental nine-amino-acid peptide with uncertain sleep-signaling targets.
Typical reported dose: 500 mcg at bedtime
- Morning infusion: 25 nmol/kg: 25 nmol/kg IV over 20 minutes one infusion on the active crossover day, into a vein. Studied in a trial. Studied in: Six healthy adults, four men and two women. (source)
- Bedtime crossover: 25 nmol/kg: 25 nmol/kg IV over 4 minutes on active nights in P-D-P or D-P-D sequence, into a vein. Studied in a trial. Studied in: Six middle-aged adults with chronic insomnia. (source)
- Single evening infusion: 25 nmol/kg IV over 4 minutes single dose, into a vein. Studied in a trial. Studied in: Healthy volunteers and adults with insomnia in five small experiments. (source)
- Four evening infusions: 25 nmol/kg IV over 4 minutes on four evenings once daily for four consecutive evenings, into a vein. Studied in a trial. Studied in: Healthy volunteers and adults with insomnia in five small experiments. (source)
- Six morning infusions: 25 nmol/kg IV on six consecutive mornings once daily for six mornings, into a vein. Studied in a trial. Studied in: Healthy volunteers and adults with insomnia in five small experiments. (source)
- Seven nights: 30 nmol/kg: 30 nmol/kg IV each night on laboratory nights 3-9 once nightly for seven consecutive nights, into a vein. Studied in a trial. Studied in: 14 middle-aged adults with chronic insomnia. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to DSIP
- Ipamorelin: An experimental peptide that triggers growth hormone release.
- Selank: A Russian nasal anxiety peptide with uncertain long-term benefit and safety.
- CJC-1295 without DAC: A peptide intended to trigger growth hormone release, with no human dosing study found.
- Pinealon: A peptide with unproven brain benefits and no established injection dose.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Download medicine data, European Medicines Agency · European Medicines Agency · 2026
- FDA Briefing Document: Emideltide-Related Bulk Drug Substances (Emideltide (free base) and Emideltide acetate), U.S. Food and Drug Administration · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- Sepsis, NHS · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Anaphylaxis, NHS · NHS · 2023
- Low blood sugar (hypoglycaemia), NHS · 2023
- [Using deltalicin for the treatment of patients with diabetic retinopathy]., Kresiun NV et al. · Eksperimental'naia i klinicheskaia farmakologiia · 2014
- The influence of deltalycyn and transcranial cerebellar stimulation upon recovery of retina after photo stress in patients with diabetic retinopathy., Kresyun NV et al. · Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi · 2014
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.